ECONOMIC METHODS USED IN HEALTH TECHNOLOGY ASSESSMENT
Introduction
Decision-making process about the development of new products is fundamental for the growth and prosperity of any company, particularly in the fast changing medical device market (Ivlev et al., 2015) . Companies must innovate to be successful but this invariably carries some risk and uncertainty. In recent years, the issue of evaluation of investment effectiveness into medical devices has been intensively solved, both at national and international level (Heintz et al., 2016) due to the growing market with medical devices (Craig et al., 2014) . Johal and Williams (2007) present three groups of decision making tools/techniques, which can help policy makers in the improvement of their early decisions on the development of a new product. These three groups of techniques consist of 1. strategic and fi nancial valuation of projects (e.g., NPV, IRR, DCF), 2. weighting and scoring of products and product criteria (e.g., analytic hierarchy process (AHP) and conjoint analysis), 3. human decisionmaking (fuzzy logic, actuarial models, neural networks, technology road mapping and expert systems).
Currently, the most common and wellestablished method for the assessment of medical devices is health technology assessment (HTA). As Ciani et al. (2015) explain, HTA aims to provide policy makers with information on the clinical and economic value of health technologies (including pharmaceuticals, medical devices, clinical procedures, and organizational systems used in health care) in order to support their reimbursement or coverage decisions Rosina et al., 2014; Rogalewicz, 2016) . In fact, HTA plays the key role in informing reimbursement and pricing decisions and providing clinical guidance on the use of medical technologies across the world (Stephens, Handke, & Dshi, 2012; Rogalewicz, Bartak, & Kubatova, 2015) .
One of the important methods of HTA is an economic evaluation which comprises a number of economic methods. The economic evaluation (EE) is a comparison of the costs and consequences of at least two choices (Drummond et al., 2005) . With respect to new health technologies, EE compares the new health technology against the current standard-of-care treatment (Gavurova & Soltes, 2016; Gavurova & Vagasova, 2016) . Sometimes, EE is called a cost-effectiveness analysis as it combines an analysis of costs and clinical effectiveness (EUPATI, 2017; Canadian Agency for Drugs and Technologies in Health, 2006; Rotter, Foerster, & Bridges, 2012) .
The EE processes are well-established in HTA of pharmaceuticals but not that much in the development of medical devices (Craig et al., 2014) . The problem is that complete standardization of economic evaluations cannot be performed since the methods should be fl exible enough to be compatible with different problems in different contexts (Mathes et al., 2013; Soltes & Gavurova, 2015) . In addition, as Rotter, Foerster, and Bridges (2012) argue, several different approaches can be potentially applied in decision modelling. Drummond, Griffi n, and Tarricone (2009) in their study summarize the main reasons why assessments of devices differ from assessments of drugs, which are as follows:   many devices are diagnostic; that is why the outcome cannot be separated from the treatment and, such devices have multiple applications;   due to a short lifetime of devices, their frequent modifi cations, and the existence of "learning curves", there is unlikely to be a substantial steady-state period, during which the device could be evaluated in an RCT;   the effectiveness of a device depends both on the device itself and the way how
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it is used (e.g., the skill and experience of a doctor);   introduction of a new treatment comprising a device may have wider economic implications;   equivalent clinical evidence may not be available for all products, making comparisons diffi cult;   prices may change in the course of time since new products penetrate the market, or because of the ways, in which purchasing is held.
The purpose of this review focuses on the exploration of the economic methods, commonly used in the economic evaluation as part of health technology assessment for medical devices. On the basis of the selected original studies, the authors summarize the main economic methods used in the decisionmaking processes about the development of new medical devices and discuss their benefi ts and limitations.
Methods
The methods included a method of literature search in the acknowledged databases for economic evaluations as suggested by Thielen et al. (2016) . Search method followed the PRISMA guidelines for conducting systematic reviews (Moher et al., 2009) . To ensure optimal coverage, additional articles were found within the reference section of retrieved articles and through citation snowballing by undertaking wider searches by author name for those appearing as key publishers in the area.
The databases thus were Web of Science, MEDLINE, and Embase. The authors searched relevant studies for the following key words: economic methods AND health technology assessment, economic methods AND HTA, economic evaluation AND health technology assessment, economic evaluation AND HTA, economic methods AND medical device AND health technology assessment.
The search period started in 2000 when the studies on the research topic started to appear and ends in December of 2016. Most of the articles were found in MEDLINE (2,648), followed by Embase (1,060), and Web of Science (986). In the last one, an increase in the number of articles on the research topic was the most obvious.
Articles that met the inclusion criteria of the quality of research papers were evaluated according to adequate description of the theoretical framework, background, and methodology (Mays & Pope, 2000) .
For those papers that fulfi lled the criteria for quality, data was extracted according to the following content: date published, study funding source, possible confl icts of interest, study objectives, target population, application of tool, site/setting, study focus, HTA tool proposed or approach used in the paper, description of tool or approach, stand alone or support tool, aspects of clinical effectiveness, costs, and contextual issues, addressed by tool or approach, all stakeholders involved, literature search incorporated, results of implementation, and focus on medical technology/intervention.
Although the number of articles on the research topic is growing, most of the studies focused on the economic evaluations of pharmaceuticals and treatment. The inclusion criteria were as follows: the study was included if it were written in English, if it was original research study, not a review, if it covered the designated period, i.e., 2000-2016, and if it concerned the research topic, i.e., economic methods used in HTA for medical devices. In this review, the product is a medical device and it refers to a class II device (e.g., blood pressure monitors, contact lenses, pregnancy test kits, single-use surgical instruments, catheters), a class III device (e.g., ventilators, cardiac monitors, hip implants, knee implants, lasers, chlamydia test kits, glucose meters), or a class IV device (e.g., defi brillators, pacemakers, coronary stents, HIV test kits, neurosurgical shunts) that requires product licensing for general marketing purposes. The original research articles or clinical studies, however, were considered only back to the years of 2014-2016 since several review studies on this topic had been made before or even in this period, e.g., (Cooper et al., 2013; Craig et al., 2014; Markewicz, van Til, & Ijzerman, 2014; Mathes et al., 2013; Pham et al., 2014; Rotter, Foerster, & Bridges, 2012; Stephens, Handke, & Dshi, 2012) .
Thus, after the identifi cation of the relevant studies on the basis of their key words and their titles, the duplicated studies were excluded. Afterwards, the abstracts were screened and, eventually, only 39 remained for the full-text analysis, out of which 11 studies were then used for a detailed analysis of the economic methods. The fi ndings from the selected studies are discussed and compared in the part on Discussion.
Findings
The search retrieved 4,694 papers in total, out of which eleven fulfi lled the inclusion criteria (PRISMA fl owchart, Fig. 1 ). Data was extracted from the eleven papers published between 2000 and 2016.
Altogether 11 studies were identifi ed according to the inclusion criteria described above. Nine studies were randomized controlled trials (Ashby et al., 2014; Downing et al., 2015; Harron et al., 2016; Lall et al., 2015; Murray et al., 2014; Rosenthal et al., 2015; Smulders et al., 2016; Walter et al., 2015) , usually comparing clinical benefi ts and cost-effectiveness of the traditional device with a new developed one, one study was a prospective study (Dozet et al., 2016) , using a cost-minimization analysis for societal impact reasons, and one was a survey (Heintz et al., 2016) , conducted among 33 European countries, which are involved in the European Network for Health Technology Assessment. The aim of this survey was to provide a general framework for economic evaluation at a European level. In the majority of the studies (9 studies) a cost-effectiveness was used. In some of these studies it was accompanied by a cost-utility analysis (3 studies), one study exclusively exploited the cost-utility analysis and one cost-minimization analysis. The studies are presented in alphabetical order of their fi rst author. Consult Tab. 1 below.
Discussion
As the fi ndings in Tab. 1 indicate, the most common economic method used in the economic evaluation of the medical device development is the cost-utility analysis (cf. Ashby et al., 2014; Downing et al., 2015; Heintz et al., 2016; Lall et al., 2015; Murray et al., 2014; Rosenthal et al., 2015; Smulders et al., 2016) , followed by the cost-effectiveness analysis (cf. Downing et al., 2015; Dozet et al., 2016; Heintz et al., 2016; Rosenthal et al., 2015) , the cost-minimization analysis (cf. Dozet et al., 2016; Heintz et al., 2016) , and the costconsequence analysis (cf. Heintz et al., 2016) . These fi ndings are in compliance with other research studies on this topic such as Brockis et al. (2006) or Mathes et al. (2013) . The cost-utility analysis (CUA) is mostly preferred and widely accepted because it enables a comparison between different indications and types of health technology, especially in state-funded health care systems. Its outcomes are measured as health-related preferences, described as Quality Adjusted Life Years (QALYs) gained. CUA is used when interventions can infl uence the health related quality of life and the length of life (Canadian Agency for Drugs and Technologies in Health, 2006) . In addition, CUA aims at a higher level of standardization because the same denomination is used for all types of health technology and the methods to determine it can be better standardized (Mathes et al., 2013) . As the survey study (Heintz et al., 2016) reveals, most European countries use CUA as the main type of economic analysis. CUA is considered to be better at providing a more complete analysis of total benefi ts than the cost-benefi t analysis, which aims at estimating the strengths and weaknesses of alternatives (Gavurova & Vagasova, 2016) . However, CUA has certain limitations. As Penner (2017) states, it relies on estimates of QALYs (for further discussion of QALY in HTA Rogalewicz and Bartak (2017) ) which may not be relevant for application in the CUA. Furthermore, there may be confl icting ideas about how to approach the assessment of human life and disability (Soltes & Gavurova, 2015) . Another problem seems to be the absence of incorporating the patient's willingness to pay in decisions to fi nance new treatments (NICE, 2013) .
The second mentioned and commonly used economic method is the cost-effectiveness analysis (CEA), which could be implemented as a secondary analysis when the use of an important patient outcome measure (other than a QALY gained) could be justifi ed if there is evidence of a meaningful difference in such an outcome compared with alternatives 8. As Weintraub and Cohen (2009) claim, CEA is an approach that can be used to extend the understanding of effi cacy data, which are frequently retrieved from RCTs. If it is relevantly applied, in some cases it may be more benefi cial than comparisons of cost alone, sometimes called cost-minimization studies, which implicitly suggest equivalence of effi cacy. There are also limitations of CEA in terms of methodological diffi culties such as measurement. CEA results can be only compared with the results of other technologies that are expressed in the same outcome measure. In addition, there might be ethical issues about the low acceptance of valuing health in monetary units in some societies (Mathes et al., 2013) . Both CEA and CUA are expressed as an incremental cost-effectiveness ratio (ICER), i.e., the ratio of change in costs to the change in effects (What is the incremental cost-effectiveness ratio (ICER, 2017) .
The third method implemented in the studies in Tab. 1 is the cost-minimization analysis (CMA). This method focuses on measuring and comparing the costs of different medical interventions. Thus, for example, the Scottish Medicines Consortium (SMC) recommend the use of CMA for therapeutically equivalent treatments established through non-inferiority studies; indirect comparisons showing statistically insignifi cant difference; or where cost-utility analysis shows extremely small quality-adjusted life year differences between treatments, however, the comparators must be appropriate and effectiveness must be comparable (Marshall et al., 2015) . The principal limitations of this cost evaluation method are that it can only be used to compare treatments that provide the same benefi ts or effectiveness (identical outcomes, e.g., therapeutic effects); moreover, costs need to be determined accurately. In this way, a decision maker can choose the treatment with the lowest total cost. The assessment of costs is performed by identifying the study's perspective, all the resources used, and quantifying them into physical units (Duemas, 2013) .
The last method mentioned in Tab. 1 is the cost-consequence analysis (CCA), which provides disaggregated costs and a range of outcomes such as intervention costs, hospital costs, clinical benefi ts, and adverse effects (Drummond et al., 2005) . It can be benefi cial for illustrating the impact of the intervention and it can be used as intermediate step for another type of evaluation. On the contrary, CCA is demanding for aggregating, weighing, and valuing the components on the user of the study Ekonomika a management (Canadian Agency for Drugs and Technologies in Health, 2006) .
Apart from the methods discussed in Tab. 1, other economic methods are sometimes used, for example, the cost-benefi t analysis or the Headroom Method. The cost-benefi t analysis (CBA) values costs and outcomes in monetary terms. In this method all direct and indirect costs of health care are included as well as economic valuations of the outcomes. However, only economic distinctions are made between the value to society or individuals of having particular health outcomes. That is why there are ethical issues connected with assigning monetary values to health outcomes (Sinkey & Odibo, 2016) .
The Headroom Method is especially important in the early assessment of the medical device since it can reveal whether the device will be commercially viable in the healthcare market. This is usually done by estimating the maximum reimbursable price (MRP) for a new device idea, and comparing this reimbursement opportunity with a developer's expected costs (Chapman, Taylor, & Girling, 2013; Girling et al., 2015) .
Overall, as this study and other research studies indicate, CUA and CEA are preferred methods in the economic evaluations. As Mathes et al. (2013) suggest the comparator should be usual care. They recommend discounting rates range from 1.5-5% for effects
Aim of the method
Conditions for applying the analysis
Benefi ts Limitations
CBA Facilitate effi cient allocation of social resources.
Costs and benefi ts are identifi ed and judged from the perspective of the company.
It expresses the degree of benefi t of the program, while quantifying the benefi ts of monetary indicators. It is possible to compare procedures with different types of outcomes. CMA Find a treatment procedure whose costs are the lowest. It is the simplest of the one-criterion costoutput methods.
Only to compare costs and not the outputs.
Procedures must be of comparable effectiveness -the same outcomes.
Tab. 2: Comparison of methods -Part 1
and 3-5% for costs although it is desirable to use the same rate for costs and effects. In addition, the recently developed Headroom Method is recommended to be used in the early assessment of the medical device development since it uses broader estimates of potential by determining the maximum reimbursable price of the new device. In fact, it is tailored to the early assessment needs of medical device (Mays & Pope, 2000) , which is essential in the manufacturers' decision-making process and other potential stakeholders. Fig. 1 below illustrates a possible hierarchical implementation model of the economic methods used in the economic evaluations of the medical device development.
ICER Show how much more funds are needed to achieve additional therapeutic benefi t.
It is the ratio of cost differences and effi ciency.
Use for CEA. None.
QALY Determine which treatment will bring one year of life to the highest possible quality at the lowest possible price. 
Ekonomika a management
Conclusions
As the fi ndings of this study show, there are several methods of economic evaluation whose selection depends on the research question, the condition of interest, and the availability of data on outcomes.
In comparison with the obtained results, the CEA, CMA, CUA, ICER and QALY methods are used in the Czech Republic for cost effectiveness evaluation.
A cost-effective procedure is then a procedure which, at comparable costs, brings about the same or higher therapeutic effect of extending life, improving the quality of life, or improving the essential measurable criterion of the disease in question. Or a tactical procedure which, with at least a comparable therapeutic effect, means lower overall costs for the health insurance system (Section 15 (8) of the Public Health Insurance Act).
As in other areas of health care (Maresova, Klimova, & Kuca, 2015; Maresova et al., 2015a,b; there is an urgent need to conduct the early assessment of the medical device development in order to avoid negatively high costs and prevent a failure rate at each stage of the development process. 
